New hope ...

… through a revolutionary study in pancreatic cancer diagnostics.

The use of the VivaScope 2500 enables gentle evaluations in real time, the connection of worldwide experts through telemedicine and thus personalised therapy options.


Pancreas cancer



Most pancreatic cancers are a death sentence. In 2021, 19,400 people developed the disease, of which 18,000 died. With a 5-year survival rate of only 5 %, pancreatic cancer is therefore the fourth most common cause of cancer death in Western countries. However, with early detection, this rate can be increased to 20 %, which is why early detection with accurate diagnosis is crucial and thus has a significant impact on clinical behaviour.

Munich-based VivaScope GmbH has achieved excellent results with its VivaScope 2500 laser scanning microscope in a study. This 81-patient study investigated the diagnostic performance of VivaScope technology in predicting the histological suitability of EUS-FNA/FNB specimens in solid pancreatic lesions and the agreement with the final histological assessment.

Revolutionary study results

The result can be seen as a revolution and gives hope to pancreatic cancer patients:

VivaScope sensitivity was 100%, specificity 66.7%, accuracy 97%, positive predictive value 97% and negative predictive value 100%.
The VivaScope 2500 represents a new technique that can be successfully applied to cytological microhistological specimens. It provides immediate information on the suitability of the tissue and shows very good agreement with the final histology. In a subsequent study, the EUS-FNA/FNB VivaScope images were evaluated by pathologists from 10 international centres to investigate the concordance between the observers with the final diagnostic report.

The main advantages of the new approach are:

- Evaluation in real time, intraoperatively, on site or remotely
- Prompt feedback on the pathological status of the removed tissue, allowing immediate treatment to be initiated
- Complete tissue integrity for subsequent laboratory analysis
- Sample preparation does not require a specialised operator
- Significant time & cost savings
- Possibility of remote diagnosis via telemedicine

Procedure in comparison:

Bisherige Methoden, insbesondere nicht-invasive Methoden, hatten Schwierigkeiten bei der Erkennung kleiner Läsionen und der Unterscheidung zwischen verschiedenen Typen. Zudem sind die konventionellen Diagnoseverfahren zeitaufwändig, bedienerabhängig und benötigen eine schnelle Beurteilung vor Ort, die jedoch nicht immer verfügbar ist.
Die Münchner VivaScope GmbH liefert mit ihrem konfokalen Laserscanmikroskop VivaScope 2500 ein diagnostisches Instrument, das eine schnelle, einfache und präzise mikroskopische Gewebeuntersuchung ermöglicht.
In der Publikation beschreiben die Autoren die Möglichkeit und die Vorteile der Verwendung des
Previous methods, especially non-invasive methods, have had difficulty in detecting small lesions and distinguishing between different types. In addition, conventional diagnostic methods are time-consuming, operator-dependent and require rapid on-site assessment, which is not always available.
With its confocal laser scanning microscope VivaScope 2500, Munich-based VivaScope GmbH provides a diagnostic instrument that enables fast, simple and precise microscopic tissue examination.
In the publication, the authors describe the possibility and advantages of using the
VivaScope 2500 to overcome the major challenges of intraoperative evaluation of cytological and microhistological specimens.

Seminars and Training

VivaScope GmbH offers, in collaboration with Competence Centres, a well-designed and comprehensive training programme about confocal laser scanning microscopy and how to use the VivaScope products to their users.
VivaScope GmbH
Stahlgruberring 5
81829 Munich

Phone: +49 (0) 89 401921 – 600
Fax: +49 (0) 89 401921 – 649

Managing Director: Christian Stoian

Contact Us

    *Mandatory details are those indicated by an asterix.